Edesa Biotech, Inc. reported financial results for the three and nine months ended June 30, 2025, on August 8, 2025. For the three months, total operating expenses remained at $1.9 million, consistent with the prior year quarter. The net loss for the quarter was $1.7 million, or $0.25 per common share, compared to $1.7 million, or $0.52 per common share, in the prior year quarter.
For the nine months ended June 30, 2025, total operating expenses decreased by $0.6 million to $5.4 million from $6.0 million in the prior year period. The net loss for this period was $5.0 million, or $0.95 per common share, compared to $5.2 million, or $1.64 per common share, in the prior year period. Total other income decreased due to lower Canadian government grant income and interest income.
As of June 30, 2025, Edesa maintained $12.4 million in cash and cash equivalents and $12.1 million in working capital. The company continued to advance manufacturing-related activities for its EB06 Phase 2 study for vitiligo, with drug manufacturing data anticipated to be submitted to the FDA for its IND application by the end of calendar 2025. Additionally, the first randomizations for the U.S. government-funded 'Just Breathe' platform study of EB05 for ARDS were completed during the quarter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.